[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:t-9-22-q34-1-q11-2":3},{"name":4,"total":5,"recruiting":6,"trials":7},"t(9;22)(q34.1;q11.2)",14,9,[8,16,23,29,35,41,47,53,59,65,72,77,83,89],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04925479","Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:57.705506Z","2026-07-05T05:32:16.796686Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05007873","ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",[20],"Phase 2","2026-08-03T02:39:51.946262Z","2026-05-05T02:43:29.710118Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06817720","Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[20],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.285437Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06236724","Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",[20],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:29.199644Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.640935Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06124157","A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)",[20],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.515234Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07269470","Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[20],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:28.219978Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT04838041","Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",[20],"2026-08-26T02:16:00.194860Z","2026-05-05T02:43:27.920762Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT01746836","Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",[20],"2026-08-26T02:19:12.219640Z","2026-04-29T02:57:57.143397Z",{"nct_id":66,"title":67,"phases":68,"status":70,"updated_at":51,"content_modified":71},"NCT07674823","Phase 1 Study Of KITE-753 in R\u002FR B-Cell ALL",[69],"Phase 1","NOT_YET_RECRUITING","2026-07-05T03:45:20.436191Z",{"nct_id":73,"title":74,"phases":75,"status":70,"updated_at":51,"content_modified":76},"NCT07614022","A Phase I Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive ALL",[69],"2026-05-29T15:36:40.232902Z",{"nct_id":78,"title":79,"phases":80,"status":70,"updated_at":81,"content_modified":82},"NCT07604233","Phase 1\u002F2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",[12],"2026-08-26T02:16:56.877406Z","2026-05-29T15:36:40.222318Z",{"nct_id":84,"title":85,"phases":86,"status":70,"updated_at":87,"content_modified":88},"NCT07178912","Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and\u002For BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)",[20],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.335420Z",{"nct_id":90,"title":91,"phases":92,"status":93,"updated_at":94,"content_modified":95},"NCT06773936","Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:15:24.145250Z","2026-06-16T05:54:07.771453Z"]